Hijazi Y - Search Results

1

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.

Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. Tillner J, et al. Among authors: hijazi y. Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16. Diabetes Obes Metab. 2019. PMID: 30091218 Clinical Trial.

2

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.

Eriksson O, Haack T, Hijazi Y, Teichert L, Tavernier V, Laitinen I, Berglund JE, Antoni G, Velikyan I, Johansson L, Pierrou S, Wagner M, Tillner J. Eriksson O, et al. Among authors: hijazi y. Sci Rep. 2020 Oct 7;10(1):16758. doi: 10.1038/s41598-020-73815-5. Sci Rep. 2020. PMID: 33028880 Free PMC article. Clinical Trial.

3

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M. Hijazi Y, et al. Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514. Curr Clin Pharmacol. 2018. PMID: 29773068 Free PMC article. Clinical Trial.

4

Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges.

Hijazi Y. Hijazi Y. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):163-172. doi: 10.1007/s13318-020-00664-y. Epub 2021 Jan 1. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33386550

5

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P. Klinger M, et al. Among authors: hijazi y. Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16. Blood. 2012. PMID: 22592608 Free article. Clinical Trial.

6

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.

Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M. Nägele V, et al. Among authors: hijazi y. Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017. Exp Hematol Oncol. 2017. PMID: 28533941 Free PMC article.

7

Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.

Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M. Xu Y, et al. Among authors: hijazi y. CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):507-15. doi: 10.1002/psp4.12003. Epub 2015 Aug 22. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26451330 Free PMC article.

8

Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.

Hijazi Y, Welker H, Dorr AE, Tang JP, Blain R, Renzetti LM, Abbas R. Hijazi Y, et al. J Clin Pharmacol. 2004 Dec;44(12):1368-78. doi: 10.1177/0091270004270147. J Clin Pharmacol. 2004. PMID: 15545307 Clinical Trial.

9

Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers.

Hijazi Y, Welker H, Dorr AE, Frank K, Renzetti LM, Patel I. Hijazi Y, et al. Eur J Clin Pharmacol. 2006 Jan;62(1):83-5. doi: 10.1007/s00228-005-0067-x. Epub 2005 Dec 21. Eur J Clin Pharmacol. 2006. PMID: 16369813 Clinical Trial. No abstract available.

10

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, Stingl G, Jung T. Skvara H, et al. Among authors: hijazi y. J Clin Invest. 2008 Sep;118(9):3151-9. doi: 10.1172/JCI35636. J Clin Invest. 2008. PMID: 18688284 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters